ERBB2 and triple-negative breast carcinoma: While the majority of breast cancers are sensitive to the endocrine therapy, patients with triple-negative breast cancer (TNBC) exhibit poor outcomes as the subtype lacks effective therapeutic targets including ER, PR and human epidermal growth factor receptor 2 (HER2)/ErbB2.